Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy).
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Dovitinib (Primary)
- Indications Glioblastoma
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Nov 2017 Status changed from active, no longer recruiting to completed.
- 07 Aug 2017 Planned End Date changed from 1 May 2016 to 1 Oct 2017.